Evidence map›Paper›PMID 29029432›Full record

ArticleOncotarget2017

The involvement of Nrf2 in the protective effects of (-)-Epigallocatechin-3-gallate (EGCG) on NaAsO

Xiao-Dong Han, Yan-Yan Zhang, Ke-Lei Wang, Yong-Pan Huang, Zhong-Bao Yang, Zhi Liu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Xiao-Dong HanDepartment of Anesthesia, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
Yan-Yan ZhangDepartment of Pharmacology, Guizhou Medical University, Guiyang, Guizhou 550004, China.
Ke-Lei WangDepartment of Pharmacology, Guiyang Nursing Vocational College, Guiyang, Guizhou 550025, China.
Yong-Pan HuangDepartment of Pharmacology, School of Medicine, Hunan Normal University, Changsha, Hunan 410013, China.
Zhong-Bao YangDepartment of Pharmacy, Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan 410006, China.
Zhi LiuDepartment of Urology Surgery, The Second Affiliated Hospital of Guizhou Medical University, Kaili, Guizhou 556000, China.
Affiliated Hospital of Guizhou Medical University · CNCentral South University · CNGuiyang Medical University · CNHunan Normal University · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arsenic exposure produces hepatotoxicity. The common mechanism determining its toxicity is the generation of oxidative stress. Oxidative stress induced by arsenic leads to the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. (-)-Epigallocatechin-3-gallate (EGCG) possesses a potent antioxidant capacity and exhibits extensive pharmacological activities. This study aims to evaluate effects of EGCG on arsenic-induced hepatotoxicity and activation of Nrf2 pathway. Plasma activities of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and lactate dehydrogenase were measured; Histological analyses were conducted to observe morphological changes; Biochemical indexes such as oxidative stress (Catalase (CAT), malonyldialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), reactive oxygen species (ROS)), Nrf2 signaling related genes (

Indexed as

(-)-Epigallocatechin-3-gallate (EGCG)hepatotoxicityNaAsO2nuclear factor erythroid 2-related factor 2 (Nrf2)oxidative stress

Identifiers

PMID29029432
PMCPMC5630332
OpenAlexW2662182613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.